Tag: BAVENCIO
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
“New Starts Here”: AGHA launches national platform for gift and homewares
Australia’s peak organisation for the gift and homewares sector, the Australian Gift & Homewares Association (AGHA), has revealed plans for a major expansion in 2026, introducing Gifted Melbourne 2026 to complement the long-established AGHA Sydney Gift Fair.
